Global Blood and Plasma Collections and Use 2023–2024: Trends, Regulations, and Market Insights
Dana Miloslavich, Director Of Research at The Marketing Research Bureau Inc, shared on LinkedIn:
“The Marketing Research Bureau is pleased to announce the completion of the following report:
GLOBAL BLOOD AND PLASMA COLLECTIONS AND USE – 2023/2024
This new MRB report presents a global overview of blood collections and an analysis of all the sources of plasma used for fractionation from over 85 countries.
Plasma collection regulations and the historical context for those regulations are detailed in many countries, including plasma recovered from whole blood donations, as well as source plasma collected by public/non-profit entities and private companies.
Today, most of the plasma for fractionation is collected in the United States, but high collection costs constitute a cause of concern for those markets that largely depend on U.S. plasma.
Therefore, a good understanding of the potential for sourcing plasma from outside the U.S. is essential for planning and forecasting. In addition, awareness of plasma volumes collected in each individual country helps to inform both its current self-sufficiency level and quantities of imported plasma proteins needed to address its domestic market needs.
In addition to data on plasma for fractionation and whole blood collections, quantitative information on other blood components is included for those countries where such figures could be accessed.
Presented data are based on an extensive survey conducted by MRB in over 85 countries in 2023 and 2024. In addition to 2024 full-year figures for plasma fractionation, the report provides historical data going back 10 or more years as available”
Read more here.
More insights on Hemostasis Today.
-
Dec 17, 2025, 15:24Laura Dormer on a Motor Relearning Program for Chronic Stroke Patients
-
Dec 17, 2025, 15:01WSO: United Nations Has Formally Adopted the Political Declaration on NCDs and Mental Health
-
Dec 17, 2025, 14:44Bryan Unger: 1st Patient Has Been Enrolled in NuvOx Therapeutics’ Phase IIb NOVEL Trial
-
Dec 17, 2025, 14:29Sarah Richardson: Feeling So Proud to Be a Part of the Advocacy Team for the HFA
-
Dec 17, 2025, 06:28Wolfgang Miesbach on Linus Völker’s Presentation of Caplacizumab as Frontline Therapy for iTTP
-
Dec 17, 2025, 06:11Lisa Murphy Thanks Stroke Foundation Team for An Impactful, Rewarding and Incredible Year
-
Dec 17, 2025, 06:05Emmanuel J Favaloro Shares A Study on AI and Machine Learning in Thrombosis and Hemostasis
-
Dec 17, 2025, 05:54Michael Bruckman: Fantastic to See Platelet-Inspired Nanoparticles Gaining Attention!
-
Dec 17, 2025, 04:00Peter Verhamme on Genetic Predisposition to Thromboembolism and COVID